NHS Approves World-First Drug to Delay Onset of Type 1 Diabetes

The National Health Service (NHS) in England and Wales has approved teplizumab, a groundbreaking immunotherapy that can delay the onset of type 1 diabetes by up to three years. This is the first treatment of its kind to target the root cause of the disease rather than merely managing its symptoms, marking a significant shift in diabetes care since the discovery of insulin over a century ago.

Teplizumab, also known as Tzield and manufactured by Sanofi, is approved for adults and children aged eight and older who are in the early, pre-symptomatic stage (stage 2) of type 1 diabetes. The drug works by training the immune system to stop attacking insulin-producing cells in the pancreas. It is administered as a daily intravenous infusion over 30 minutes for 14 consecutive days, with no further treatment required after the course is completed.

The National Institute for Health and Care Excellence (Nice) described the approval as "genuinely exciting" and a major step forward. The decision is expected to benefit hundreds of children and young people each year, offering them precious time before they must begin lifelong insulin management. Karen Addington, chief executive of the charity Breakthrough T1D, called it an "incredible moment," adding that the treatment gives families the chance to "do everything possible to give them more years without the daily burden of managing this relentless condition."

Type 1 diabetes occurs when the immune system attacks the pancreas, leading to little or no insulin production. Patients must constantly monitor blood glucose and administer insulin, either through injections or a pump. Dr Elizabeth Robertson, director of research at Diabetes UK, hailed the approval as "the start of a new age of type 1 diabetes treatment," emphasizing that for the first time in 100 years, a medicine targets the root cause of the condition.

The drug is available via a confidential discounted pricing agreement between Sanofi and NHS England. However, eligibility currently depends on early detection through blood tests, which are not yet part of a routine national screening program in the UK. Charities are campaigning for a national screening program similar to one already in place in Italy, which would help identify high-risk individuals before symptoms appear. Most newly diagnosed patients have no close family history of the disease, suggesting environmental factors may also play a role in triggering it.